T. Rowe Price Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $821M | Sell |
|
|||||
|
2025
Q2 | $1.03B | Sell |
|
|||||
|
2025
Q1 | $946M | Buy |
|
|||||
|
2024
Q4 | $781M | Sell |
|
|||||
|
2024
Q3 | $949M | Sell |
|
|||||
|
2024
Q2 | $848M | Sell |
|
|||||
|
2024
Q1 | $551M | Buy |
|
|||||
|
2023
Q4 | $667M | Sell |
|
|||||
|
2023
Q3 | $695M | Buy |
|
|||||
|
2023
Q2 | $738M | Sell |
|
|||||
|
2023
Q1 | $796M | Sell |
|
|||||
|
2022
Q4 | $968M | Buy |
|
|||||
|
2022
Q3 | $745M | Sell |
|
|||||
|
2022
Q2 | $1.02B | Buy |
|
|||||
|
2022
Q1 | $1.11B | Buy |
|
|||||
|
2021
Q4 | $1.11B | Buy |
|
|||||
|
2021
Q3 | $1.11B | Buy |
|
|||||
|
2021
Q2 | $937M | Sell |
|
|||||
|
2021
Q1 | $787M | Sell |
|
|||||
|
2020
Q4 | $725M | Sell |
|
|||||
|
2020
Q3 | $876M | Sell |
|
|||||
|
2020
Q2 | $929M | Sell |
|
|||||
|
2020
Q1 | $684M | Buy |
|
|||||
|
2019
Q4 | $616M | Buy |
|
|||||
|
2019
Q3 | $393M | Buy |
|
|||||
|
2019
Q2 | $255M | Buy |
|
|||||
|
2019
Q1 | $326M | Sell |
|
|||||
|
2018
Q4 | $268M | Sell |
|
|||||
|
2018
Q3 | $368M | Sell |
|
|||||
|
2018
Q2 | $514M | Sell |
|
|||||
|
2018
Q1 | $1.5B | Buy |
|
|||||
|
2017
Q4 | $1.55B | Buy |
|
|||||
|
2017
Q3 | $1.01B | Buy |
|
|||||
|
2017
Q2 | $532M | Buy |
|
|||||
|
2017
Q1 | $214M | Buy |
|
|||||
|
2016
Q4 | $156M | Buy |
|
|||||
|
2016
Q3 | $273M | Buy |
|
|||||
|
2016
Q2 | $222M | Buy |
|
|||||
|
2016
Q1 | $80.6M | Buy |
|
|||||
|
2015
Q4 | $117M | Sell |
|
|||||
|
2015
Q3 | $106M | Sell |
|
|||||
|
2015
Q2 | $205M | Buy |
|
|||||
|
2015
Q1 | $132M | Buy |
|
|||||
|
2014
Q4 | $120M | Sell |
|
|||||
|
2014
Q3 | $249M | Sell |
|
|||||
|
2014
Q2 | $205M | Sell |
|
|||||
|
2014
Q1 | $241M | Sell |
|
|||||
|
2013
Q4 | $245M | Sell |
|
|||||
|
2013
Q3 | $271M | Buy |
|
|||||
|
2013
Q2 | $71.6M | Buy |
|